hero-banner
hero-banner
On-demand

Establish MAM to track the cause of color change in a protein therapeutic

#C6C6C6
horizontal
sciextext
text-left

Learn about the link between AGE formation and color change in final drug products. Explore how to develop assays that enable rapid monitoring and tracking of these post-translational modifications (PTMs).

Because a product quality attribute (PQA) may impact efficacy and safety, the color of a protein therapeutic under process development, and any changes to that color, require close monitoring.

This webinar discusses the use of a LC-MS workflow for detailed peptide mapping of PTMs to:

  • Define potential PQAs associated with color change
  • Investigate the link between color change and advanced glycan end products (AGEs)
  • Characterize and localize AGEs linked to color change
  • Establish a MAM to quantitatively track AGEs
registerform
https://forms.sciex.com/f/lp?campaign_id=7013w000002MOPOAA4&utm_term=G-%20Janssen%20Intabio%20Color%20Change%20Mahan%20WOD%20-%200524&market_vertical=Biopharma&utm_campaign=Protein%20therapeutic%20workflows,%20leadership&utm_source=SCIEX.com&solution=MS&requesttype=WOD&utm_content=WOD&ty=https://sciex.com/events/biopharma/wod-protein-therapeutic-color-change/thank-you&show_mv=true
one-column
1050px
Presented by:

Andrew D. Mahan PhD

Mass Spec group leader
Cell Engineering and Analytical Sciences
J&J Innovative Medicines